Cargando…

Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) poses a significant global health concern, with its incidence steadily increasing. The development of HCC is a multifaceted, multi-step process involving alterations in various signaling cascades. In recent years, significant progress has been made in understanding the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bang, Jieun, Jun, Mihyeon, Lee, Soyun, Moon, Hyuk, Ro, Simon Weonsang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458925/ https://www.ncbi.nlm.nih.gov/pubmed/37631344 http://dx.doi.org/10.3390/pharmaceutics15082130

Ejemplares similares

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
por: Tian, Ling-Yu, et al.
Publicado: (2023)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
por: Ratti, Stefano, et al.
Publicado: (2022)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling
por: Dai, Ninggao, et al.
Publicado: (2018)

EDG2 enhanced the progression of hepatocellular carcinoma by LPA/PI3K/AKT/ mTOR signaling
por: Xu, Meng, et al.
Publicado: (2017)

Apoptotic Effects of Xanthium strumarium via PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma
por: Kim, Juyoung, et al.
Publicado: (2019)

EGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell Line
por: Treda, Cezary, et al.
Publicado: (2016)

MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
por: Moon, Hyuk, et al.
Publicado: (2021)

The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
por: Su, Hengchuan, et al.
Publicado: (2013)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis
por: Ge, Fengmei, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
por: Darici, Salihanur, et al.
Publicado: (2020)

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
por: Li, Huayi, et al.
Publicado: (2021)

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
por: Alves, Carla L., et al.
Publicado: (2023)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin
por: Ou, Da-Liang, et al.
Publicado: (2014)

Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
por: Skolariki, Aglaia, et al.
Publicado: (2022)

Linc01014 regulates gefitinib resistance in oesophagus cancer via EGFR‐PI3K‐AKT‐mTOR signalling pathway
por: Fu, Xiao, et al.
Publicado: (2019)

PSMC4 promotes prostate carcinoma progression by regulating the CBX3–EGFR‐PI3K‐AKT‐mTOR pathway
por: Liu, Kaifeng, et al.
Publicado: (2023)

Colon Cancer Cell Secretes EGF to Promote M2 Polarization of TAM Through EGFR/PI3K/AKT/mTOR Pathway
por: Lian, Guanghui, et al.
Publicado: (2019)

Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma
por: Westhoff, Mike-Andrew, et al.
Publicado: (2013)

PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
por: Babichev, Yael, et al.
Publicado: (2016)

The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
por: Cheaib, Bianca, et al.
Publicado: (2015)

The PI3K-AKT-mTOR pathway activates recovery from general anesthesia
por: Zhang, Yun-Hui, et al.
Publicado: (2016)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

PI3K/Akt/mTOR Signaling Pathway and the Biphasic Effect of Arsenic in Carcinogenesis
por: Chen, Qiao Yi, et al.
Publicado: (2018)

Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours
por: Xu, Fei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_np8trkta3g19bqjqrqba6ocjg8